321 related articles for article (PubMed ID: 27490802)
1. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
Bronger H; Singer J; Windmüller C; Reuning U; Zech D; Delbridge C; Dorn J; Kiechle M; Schmalfeldt B; Schmitt M; Avril S
Br J Cancer; 2016 Aug; 115(5):553-63. PubMed ID: 27490802
[TBL] [Abstract][Full Text] [Related]
2. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
3. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.
Qian L; Yu S; Yin C; Zhu B; Chen Z; Meng Z; Wang P
Pancreatology; 2019 Mar; 19(2):340-345. PubMed ID: 30685120
[TBL] [Abstract][Full Text] [Related]
4. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.
Menke J; Zeller GC; Kikawada E; Means TK; Huang XR; Lan HY; Lu B; Farber J; Luster AD; Kelley VR
J Am Soc Nephrol; 2008 Jun; 19(6):1177-89. PubMed ID: 18337479
[TBL] [Abstract][Full Text] [Related]
5. Constitutive nuclear factor kappaB activity is required to elicit interferon-gamma-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines.
Hiroi M; Ohmori Y
Biochem J; 2003 Dec; 376(Pt 2):393-402. PubMed ID: 12946268
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
7. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity and regulation of CXCL9 and CXCL10 in oral keratinocytes.
Marshall A; Celentano A; Cirillo N; Mignogna MD; McCullough M; Porter S
Eur J Oral Sci; 2016 Oct; 124(5):433-439. PubMed ID: 27671889
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of chemokine CXC receptor 3, 4 and their ligands at the early pregnancy decidua and villi].
Bai XX; Kong BH; Zhang YZ; Qu X; Wang HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):904-8. PubMed ID: 19134328
[TBL] [Abstract][Full Text] [Related]
11. Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.
Fenwick PS; Macedo P; Kilty IC; Barnes PJ; Donnelly LE
PLoS One; 2015; 10(6):e0128757. PubMed ID: 26090665
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of CXC chemokines in epithelial ovarian cancer.
Rainczuk A; Rao J; Gathercole J; Stephens AN
Reproduction; 2012 Sep; 144(3):303-17. PubMed ID: 22771929
[TBL] [Abstract][Full Text] [Related]
13. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.
Kanda N; Watanabe S
Endocrinology; 2007 May; 148(5):2317-25. PubMed ID: 17255201
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours.
Rainczuk A; Rao JR; Gathercole JL; Fairweather NJ; Chu S; Masadah R; Jobling TW; Deb-Choudhury S; Dyer J; Stephens AN
Int J Cancer; 2014 Feb; 134(3):530-41. PubMed ID: 23873303
[TBL] [Abstract][Full Text] [Related]
15. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.
Romagnani P; Rotondi M; Lazzeri E; Lasagni L; Francalanci M; Buonamano A; Milani S; Vitti P; Chiovato L; Tonacchera M; Bellastella A; Serio M
Am J Pathol; 2002 Jul; 161(1):195-206. PubMed ID: 12107104
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of CXCL9, CXCL10 and CXCL11 in renal tubular epithelial cells induced by IFN-γ].
Lin Q; Song Y; Zhu X; Yang S; Zheng J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Feb; 29(2):137-40. PubMed ID: 23388331
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
18. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma.
Ohtani H; Jin Z; Takegawa S; Nakayama T; Yoshie O
J Pathol; 2009 Jan; 217(1):21-31. PubMed ID: 18980207
[TBL] [Abstract][Full Text] [Related]
19. Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells.
Fluhr H; Seitz T; Zygmunt M
Breast Cancer Res Treat; 2013 Jan; 137(1):109-18. PubMed ID: 23160925
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
Ejaeidi AA; Craft BS; Puneky LV; Lewis RE; Cruse JM
Exp Mol Pathol; 2015 Aug; 99(1):163-72. PubMed ID: 26079660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
